non-small cell lung cancer
Conditions
Interventions
Patients will receive daily erlotinib at 150mg/day for six weeks. The patients with responsive disease considered to be technically resectable will undergo surgical resection.
Sponsors
Department of Thoracic Surgery, Tsukuba University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Histologically or cytologically proven non-small cell lung cancer 2) cStageIII-N2 3) Activating EGFR mutations 4) Without previously treatment for lung cancer 5) Has measurable by RECIST (ver. 1.1) criteria 6) ECOG performance status 0-1 7) Age >= 20 years 8) Adequate organ function Absolute neutrophil count (ANC) >= 1,500/mm3 Platelets >= 100000/mm3 Hemoglobin >= 9.0g/dL AST and ALT <= 2.5 x ULN Total bilirubin <= 1.5 x ULN Serum creatinine <= 1.5 x ULN SpO2 >= 90% 9) Life expectancy more than 3 months 10) Signed written informed consent
Exclusion criteria
Exclusion criteria: 1) Active lung disease such as interstitial pneumonia, pneumoconiosis, radiation pneumonitis, or medicine-induced pneumonitis 2) Prior exposure to agents directed at the HER axis (e.g. erlotinib, gefetinib, cetuximab, trastuzumab) 3) Gastrointestinal abnormalities, including active peptic ulcer or inflammatory bowel disease 4) Active ophthalmologic diseases (e.g. Sjogrens) 5) Neurological symptoms of spinal cord compression 6) Uncontrolled infections 7) History of severe heart disease 8) Serious medical complications 9) Multiple primary cancer 10) Serious psychiatric illness or psychological symptom 11) Women who are pregnant, lactating or with childbearing potential 12) Ineligible based on decision of an investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Radical resection rate | — |
Countries
Japan
Contacts
Public ContactShinji Kikuchi
Tsukuba University Hospital Department of Thoracic Surgery
Outcome results
None listed